| Name | Title | Contact Details |
|---|
KCAS Bioanalytical Labs is a Shawnee, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Metropolitan Health Networks, Inc. is a West Palm Beach, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
The Accreditation Council for Graduate Medical Education (ACGME) is a private, non-profit, professional organization responsible for the accreditation of approximately 10,000 residency and fellowship programs and the approximately 800 institutions that sponsor these programs in the United States. Residency and fellowship programs educate approximately 125,000 resident and fellow physicians in 150 specialties and subspecialties. The ACGME`s mission is to improve health care and population health by assessing and advancing the quality of resident physicians` education through accreditation. We imagine a world characterized by: • A structured approach to evaluating the competency of all residents and fellows, • Motivated physician role models leading all graduate medical education programs, • High-quality, supervised, humanistic, clinical educational experience, with customized formative feedback, • Clinical learning environments characterized by excellence in clinical care, safety, and professionalism, • Residents and fellows achieving specialty specific proficiency prior to graduation, • Residents and fellows prepared to become Virtuous Physicians who place the needs and well-being of patients first.
Back Nursery is a Hastings, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Glytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care. Its FDA-cleared titration software and proprietary algorithms power the only solution capable of delivering personalized diabetes treatment recommendations across the continuum of care, from hospital to home. With ongoing support from its team of doctors, nurses and technologists headquartered outside of Boston, Glytec improves outcomes and controls costs for the large population of patients requiring insulin treatment – including those with and without a diagnosis of diabetes.